Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial.
First author：Yongjun Wang, Yuesong Pan
Corresponding author：Yongjun Wang
essential_information
- Person in charge：Yongjun Wang, Yuesong Pan
- Data Sources： OTHERS
- Number of papers：OTHERS20210110
- Published time：2021-07-09
2021-07-09
Published articles
Journal：JAMA Neurology
Publication type: Article
IF(IF): 18.302
PMID: 34244703 Link To Pubmed Full text Download
Background And Purpose
To evaluate the efficacy and safety of ticagrelor-aspirin in patients with moderate (NIHSS 4-5) ischemic stroke.
Method
The THALES (The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death) trial was a randomized trial conducted at 414 hospitals in 28 countries in 2018/2019. This exploratory analysis compared stroke patients with baseline NIHSS 4-5 to those with NIHSS 0-3.
Conclusion
Patients with a moderate ischemic stroke have consistent benefit from ticagrelor-aspirin versus aspirin alone as compared to patients with less severe ischemic stroke
Main results
The observed primary-outcome event rate in patients with moderate stroke was 7.6% (129/1,671) on ticagrelor and 9.1% (150/1,641) on placebo (HR 0.84, 95% CI 0.66 to 1.06); and 4.7% (158/3,359) on ticagrelor and 5.7% (190/3,312) on placebo in those with less severe events at presentation (HR 0.82, 95% CI, 0.66 to 1.01) (P for interaction=.88).